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Summary
Objective: This study was to use adenoviral vector-mediated nuclear factor-kBp65 (NF-kBp65)-speciﬁc siRNA (Ad-siRNANF-kBp65) to suppress
the progression of early osteoarthritis (OA) in rat model, and therefore to explore a new gene therapy for OA.
Methods: Reverse transcription polymerase chain reaction was performed to conﬁrm the silencing effect of Ad-siRNANF-kBp65 in cultured rat
chondrocytes. Transection of the medial collateral ligament plus partial medial meniscectomy was operated in the knee of rats to establish OA
model. Histological analysis was made to assess the morphological change of cartilage and synovium, and enzyme-linked immunosorbent
assay was made to measure the expression of cytokines, such as interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a), in synovial ﬂuid.
The silencing effect of Ad-siRNANF-kBp65 on NF-kBp65 in cartilage and synovium of knee was measured with Western blot and the activation
of NF-kB was measured with electrophoretic mobility shift assays.
Results: Ad-siRNANF-kBp65 can inhibit the activation of NF-kB and the expression of NF-kBp65 in cartilage and synovium of the knee, restrain
the induction of IL-1b and TNF-a in synovial ﬂuid, alleviate the inﬂammation of synovium and reduce the degradation of cartilage in early phase
of experimental OA.
Conclusions: Ad-siRNANF-kBp65 can suppress the progression of the early experimental OA which suggests that Ad-siRNANF-kBp65 has poten-
tial to be a useful preventive and therapeutic agent for OA.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a degenerative disease that affects
a large population and results in signiﬁcant morbidity and
disability. The initiating events that result in the cartilage
degradation, sclerosis of subchondral bone as well as a vari-
able degree of synovial inﬂammation that are characteristic
of OA are poorly understood. Current research attributes
these changes to a complex network of biochemical factors
that lead to a breakdown of the cartilage macromolecules1.
And pro-inﬂammatory cytokines such as interleukin-1b
(IL-1b) and tumor necrosis factor-a (TNF-a), locally pro-
duced by the inﬂamed synovium and chondrocyte, also
likely contribute to these alterations2,3. Both IL-1b and
TNF-a can elicit the activation and proliferation of cultured
synovial cells, and directly alter normal cartilage and bone
metabolism because each can induce collagenase expres-
sion in synovial cells, inhibit proteoglycan synthesis in artic-
ular chondrocytes, and stimulate bone resorption in vivo4,5.
Furthermore, IL-1b and TNF-a can induce the expression of
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174granulocyte-macrophage colony-stimulating factor (GM-
CSF)6, which play major roles in inﬂammatory responses
via the activation of a variety of transcription factors, including
nuclear factor-kB (NF-kB), activator protein-1 (AP-1), and
CAAT/enhancer binding protein (C/EBP) family members7e9.
One of the major transcriptional circuits implicated in inﬂam-
mation is the NF-kB/inhibitor of NF-kB (IkB) pathway. NF-
kB is rapidly activated by pro-inﬂammatory cytokines like
IL-1b and TNF-a, and is involved in the regulation of a large
set of inﬂammatory response genes, including various cyto-
kines and chemokines, acute-phase proteins, cell adhesion
proteins, and immunoglobulins7.
In recent years, gene therapy targeted at cytokines offers
a new hope to OA treatment, and IL-1b and TNF-a are con-
sidered to be the principal inﬂammatory cytokines10 and are
thus natural targets for therapy for OA. Therefore, the use of
biological agents that block the activity of these cytokines is
the current focus11. These agents include TNF-a soluble re-
ceptor (TNF-sR)12, IL-1 receptor antagonists (IL-1Ra)13,14,
anti-inﬂammatory cytokines15 and inhibitors of catabolic
enzyme16. As there are many pro-inﬂammatory cytokines,
oxidants and other factors exerting action in initiation and
development of OA, it is hard to get complete therapeutic
effects by blocking the activity of one or two cytokines. So
we attempted to inhibit signal pathway of NF-kB.
NF-kBp65 is a key active subunit in NF-kB transcription in
several cell types17,18, and our previous study provided ev-
idences that interference of the expression of NF-kBp65
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activation of NF-kB and the expression of matrix metallopro-
teinases-9 (MMP-9), nitric oxide synthase-2 (NOS-2) and
cyclooxygenase-2 (COX-2) in induced chondrocytes19. So
we attempted to use siRNA to interfere the expression of
NF-kBp65 in animal to explore a new therapeutic approach
for OA. At present, several techniques have been employed
to introduce siRNA into vertebrate cells and animal models,
and plasmid constructs have successfully been used to
generate intracellular siRNA20e22. To improve the efﬁciency
of the transfer of the expression cassette, recombinant ret-
rovirus, recombinant adeno-associated virus and adeno-
virus based vectors have been used to introduce the
expression cassettes into the target cells and animal mod-
els23e27. In this study, we used adenoviral vector to transfer
siRNA into the knee joints of OA model, whose medial col-
lateral ligament and partial medial meniscus were excised,
to explore the anti-arthritic effect of the NF-kBp65-speciﬁc
siRNA (Ad-siRNANF-kBp65). And we concluded that adeno-
virus mediated NF-kBp65-speciﬁc siRNA could restrain
the induction of IL-1b and TNF-a, alleviate the inﬂammation
of synovium, and reduce the degradation of cartilage in OA
model at early phase.Materials and methodsDESIGN OF HAIRPIN siRNA TEMPLATE OLIGONUCLEOTIDEThe target sequence of NF-kBp65-speciﬁc siRNA is
50-AAGAGCATCATGA AGAAGAGT-30 according to our
previous study19. Ambion’s siRNA target design online
tool was utilized to design sense and antisense DNA oligo-
nucleotides that encoded a hairpin siRNA template for the
gene of NF-kBp65; sense template: 50-TCGAGGAGCA
TCATGAAGAAGAGTTTCAAGAGAACTCTTCTTCATG
ATG CTCTTA-30, antisense template: 50-CTAGTAAGAG
CATCATGAA AAGAGTTCTC TTGAAACTCTTCTTCATG
ATGCTCC-30. Two template oligonucleotides were synthe-
sized by AuGCT Biotechnology Co., Ltd. (AuGCT, Beijing,
PR China), annealed in 50 ml DNA annealing solution
(Ambion, Austin, TX) at 90C for 3 min, then slowly cooled
to 37C and incubated at 37C for 60 min, the annealed
siRNA template insert could be ligated into shuttle vector.ADENOVIRAL VECTOR CONSTRUCTIONThe pSilencer adeno1.0-CMV System (Ambion) was
employed to produce recombination adenovirus. The
annealed siRNA template insert was ligated into shuttle
vector 1.0-CMV, identiﬁed with restriction endonuclease
Xho I and Spe I, and conﬁrmed by DNA sequence analysis.
The adenoviral Lac Z backbone plasmid and the shuttle
vector containing siRNA template were linearized with
Pac I and co-transfected into human embryonic kidney
(HEK)-293 cells using a calcium phosphate method to pro-
duce recombinant adenovirus. After adenovirus was ex-
panded in HEK-293 cells, viral particles were puriﬁed with
BD Adeno-XVirus Puriﬁcation Kits (BD Biosciences,
Mountain View, CA), viral titer was determined by optical
density at 260 nm and standard plaque assay with b-gal
staining, the rate of transfection in chondrocytes was eval-
uated with b-gal staining, the silencing effect of Ad-siRNA
was tested in chondrocytes with reverse transcription poly-
merase chain reaction (RT-PCR), and the recombinant
adenovirus was stored at 80C until used in experiment.
The empty recombinant replication-deﬁcient adenovirus(Ad-lacZ) and the recombinant adenovirus that encoded
a scrambled siRNA (Ad-siRNAscrambled), which were con-
structed in parallel, were used as control vectors throughout
the study. All endonucleases were purchased from New-
England Biolabs (Ipswich, MA, UK).CHONDROCYTES CULTURE AND GENE TRANSFECTIONArticular chondrocytes were isolated from femoral heads
and knees of Sprague Dawley (S-D) male rats (200e250 g,
Experimental Animal Center of Peking University Health
Science Center, Beijing, PR China) under aseptic condi-
tions. The primary chondrocytes were obtained by enzy-
matic dispersal of cartilage as previously described28.
Cells were seeded into Costar 24-well plates (Costar,
Corning, NY) at a ﬁnal density of 1 105 cells/well in Dul-
becco’s modiﬁed eagle medium (DMEM) (Gibco BRL,
Grand Island, NY) supplemented with 10% fetal bovine se-
rum (FBS) (Hyclone, Logan, UT) and cultured for 3 days
under normal growth conditions. Experiments were per-
formed with the ﬁrst or second passage cells. The chon-
drocytes were infected with recombinant adenovirus at 0,
10, 50, 100 and 200 multiplicity of infection (MOI) for
48 h, ﬁxed with 1% glutaraldehyde for 15 min at room tem-
perature, rinsed twice with phosphate-buffered saline
(PBS, pH 7.4), and reacted to 0.1 M sodium-phosphate
buffer, pH 7.5, 10 mM X-gal solution for 6 h at 37C.
Efﬁciency of gene transduction was assessed from micro-
scopic observation of the cells that stained blue. The chon-
drocytes were infected with recombinant adenovirus at 100
MOI for 72 h. Total mRNA was isolated to perform RT-PCR.mRNA EXPRESSION ANALYSISTotal mRNA was isolated from cultured chondrocytes
with Trizol (Invitrogen, Carlbad, CA). Isolated total RNAs
(2 mg) were reversely transcribed for 45 min at 54C and
then ampliﬁed with a commercial kit (Access RT-PCR sys-
tem, Promega, Madison, WI) in a volume of 25 ml, employ-
ing speciﬁc primers of rat NF-kBp65. PCR analysis was
conducted in the following conditions: 45 s at 94C to dena-
ture the double-stranded DNA, 45 s at 60C to allow for the
annealing of the primers and 45 s at 68C for primers exten-
sion. Ampliﬁcations were done for 35 cycles and fragments
of PCR were 243 bp. The speciﬁc primers employed were
(forward) 50-TCACCAAAGAC CCACCTCACCG-30 and (re-
verse) 50-GGACCGCATTCAAGTCATAGTCCC-30. PCR
products were separated on 1.5% agarose gels and visual-
ized by ethidium bromide staining, and DNA bands were
visualized under ultraviolet (UV) light and photographed.IN VIVO EXPERIMENTAL DESIGNNinety S-D male rats (250e300 g, Experimental Animal
Center of Peking University Health Science Center) were
used in this study, 87 rats had operation on both knees,
transection of the medial collateral ligament plus partial me-
dial meniscectomy. Three days after the surgery, rats were
used for the study. Handling and care of the animals were in
accordance with the policies of the Peking University Health
Science Center and of the National Institute of Health.
Fifteen S-D rats, which were averagely divided into ﬁve
groups, were utilized for determining the optimal therapeutic
range for Ad-siRNANF-kBp65. Both knees’ joint of rats in ﬁve
groups were transduced with one of ﬁve doses of virus (0.0,
1.6 105, 1.6 106, 1.6 107, and 1.6 108 pfu/ml). The
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centesis prior to transduction and at 7, 14, 21, 28, 35 days
after transduction. The collected synovial ﬂuids in right
joints were analyzed with enzyme-linked immunosorbent
assay (ELISA) to determine concentration of TNF-a, and
in left joints were counted the number of inﬂammatory cells
by use of routine clinicopathologic methods.
Three non-operated S-D rats were killed after transduc-
tion in knees of Ad-lacZ with 1.6 108 pfu/ml for 3 days.
The joints were dissociated, which the joint cavity was ex-
posed, and then were ﬁxed with 2% paraformaldehyde,
0.1% glutaraldehyde for 1 h at room temperature, washed
three times with PBS and reacted to 0.1 M sodium-
phosphate buffer, pH 7.5, 10 mM X-gal solution for 4 h at
37C. Reaction was stopped by washing the sample with
PBS. After the color development, samples were observed
macroscopically and took pictures.
Seventy-two operated rats were divided into ﬁve groups.
Rats in group 1 (n¼ 12) received no treatment, one arthritic
control group (group 2) of 12 rats received 1.6 108 pfu
suspensions of empty recombinant adenovirus into both
knees, another arthritic control group (group 3) of 12 rats
received 1.6 108 pfu suspensions of recombinant adeno-
virus with siRNAscrambled into both knees. Rats in group 4
(n¼ 12) were orally given aspirin (250 mg/kg/day) twice
daily at 12 h intervals. Rats in group 5 (n¼ 12) received
1.6 108 pfu suspensions of recombinant adenovirus with
siRNANF-kBp65 into both knees. A naive control group (group
6) of 12 rats was neither induced with arthritis nor given any
treatment.
At 7 and 14 days after surgery, the knees were lavaged
with PBS, levels of IL-1b and TNF-a in lavage ﬂuids were
measured using cytokine ELISA kits. At 14 days, rats
were sacriﬁced and the cartilage and synovium were dis-
sected and analyzed for effects of siRNA with histological
analysis. The protein of cartilage and synovium was ex-
tracted and examined the silencing effect with Western
blot. The nuclear protein of cartilage was isolated to make
electrophoretic mobility shift assays (EMSAs).ELISATo lavage rat knee joints, 200 ml of PBS was injected into
the joint space through the patellar tendon. After manipula-
tion of the joint, the needle was reinserted, the ﬂuid was
aspirated and stored at 80C until analysis. The levels
of IL-1b and TNF-a in lavaged ﬂuid were measured with
ELISA kits (Biosource, Camarillo, CA) according to the
manufacture’s instructions.WESTERN BLOT ANALYSISTotal proteins were extracted from the comminuted carti-
lage and synovium with Trizol (Invitrogen), and protein con-
centrations were determined using the BCA Protein Assay
Kit (Pierce) and their assay protocol. The blots were im-
mersed in 20 ml of blocking buffer [5% skimmed milk and
1%Tween-20 in Tris-buffered saline (TBST)] for 2 h at
room temperature and subsequently incubated overnight
at 4C with the primary antibodies: polyclonal anti-NF-
kBp65 (1/500) (Santa Cruz, CA), followed by a secondary
IgG (1/10,000) conjugated to horseradish peroxidase, then
were washed three times for 15 min each in 20 ml of
TBST with gentle shaking. Visualization of the immunocom-
plexes was conducted with the Luminol reagent kit (Santa
Cruz) according to the manufacturer’s speciﬁcations. Theblots imaged by autoradiography were quantiﬁed by
densitometry.NUCLEAR PROTEIN ISOLATION AND EMSAEMSA was used to study the effect of siRNA on NF-kB
activation. Nuclear proteins of cartilage were isolated using
NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Pierce, Rockford, IL) according to the manufacturer’s
protocol. The concentration of proteins in samples was
measured by the bicinchonninic acid (BCA) method. The
oligonucleotides for the NF-kB consensus sequence were
50-AGTTGAGGGGACTTTCCCAGGC-30 and 30-TCAACT
CCCCTGAAAGGGTCCG-50 which were end-labeled with
biotin (synthesized by Beijing AuGCT Biotechnology Co.,
Ltd.). Complementary oligonucleotides were annealed in
sodium Tris-Hcl EDTA (STE) buffer by slow cooling to
room temperature in boiling water. Nuclear extracts (5 mg)
were added in 20 ml of binding reactions and incubated for
20 min at room temperature. EMSAs were performed
according to the manufacture’s protocol of LightShift
Chemiluminescent EMSA Kit (Pierce). To establish the
speciﬁcity of the reaction, negative controls without cell
extracts and competition assays with a 200-fold excess of
unlabeled oligonucleotide were performed. In competition
assays, the corresponding unlabeled probe was added to
the reaction mixture 10 min before the addition of the
labeled probe.HISTOLOGICAL ANALYSISHistologic evaluation was performed on sagittal sections
of cartilage from the lesion areas on medial femoral con-
dyle. After dissection, specimens were ﬁxed in 10% buff-
ered formalin for 24 h followed by decalciﬁcation in
a mixture of 10% formic acid and 2% buffered formalin
for 7d14 days. The ﬁxed, decalciﬁed tissue was embed-
ded in parafﬁn and processed using conventional dehydrat-
ing and clearing agents, and 5-mm sections were cut to
stain with hematoxylin and eosin (H and E) and toluidine
blue.
The severity of OA lesions was graded on a scale of 0e6
by three independent observers using a modiﬁcation of the
Mankin method29, namely, grade 0, normal; grade 1, sur-
face irregularities; grade 2, pannus and surface irregulari-
ties; grade 3, superﬁcial cleft formation; grade 4, deep but
localized clefts down to bone; grade 5, large surface defects
down to bone; and grade 6, complete loss of cartilage on
the load bearing surface. The scoring system was based
on the most severe histologic changes in the multiple
sections.
Representative specimens of synovial membrane were
dissected from underlying tissues. The specimens were
ﬁxed, embedded, sectioned (5 mm) as above, and stained
with H and E and examined by light microscopy. The sam-
ples were quantitatively classiﬁed according to synovium
hypercellularity and the extent of synovitis29: grade 0, nor-
mal synovia and underlying tissues; grade 1, mild or focal
synovitis limited to surface or mild ﬁbrosis of subsynovial
tissues without synovial involvement; grade 2, moderate sy-
novitis with beginning ﬁbrosis of subsynovial tissues; grade
3, severe synovitis with moderate ﬁbrosis of underlying tis-
sues. Three synovial membranes of specimens were exam-
ined for scoring and the higher score of each was retained.
The average was calculated and considered as a unit for
the whole knee.
Fig. 1. The b-gal staining of adenovirus foci. After infection with re-
combination adenovirus 48 h, HEK-293 cells were stained with
b-gal for 24 h and a comet-shaped adenovirus foci appeared (400).
Fig. 2. The effect of Ad-siRNA on expression of NF-kBp65 in chon-
drocytes. The chondrocytes were infected with Ad-siRNA at 100
MOI for 72 h, total RNA was isolated and RT-PCR of NF-kBp65
was performed, the expression of NF-kBp65 was evidently de-
creased. Lanes 1, 2, 3, 4: infection with Ad-siRNA and lanes 5, 6,
7, 8: control.
177Osteoarthritis and Cartilage Vol. 16, No. 2STATISTICAL ANALYSISAll values, expressed as mean S.E.M., were subjected to
Student’s t test between two groups and one-way analysis
of variance (ANOVA) among multiple groups employing
the computer SPSS 10.0 statistic package, at a signiﬁcance
level of P< 0.01.ResultsTHE DESIGN OF siRNA AND PRODUCTION OF RECOMBINANT
ADENOVIRUSBecause there is gene of Lac Z in the adenovirus back-
bone plasmid, the b-gal staining was made to make out
that the recombinant adenovirus was successfully packaged
and infected into HEK-293 cells (Fig. 1). The viral titer was
8 108 pfu/ml, the rate of transfection of Ad-siRNA in chon-
drocytes at 0, 10, 50, 100 and 200 MOI was 0, 16.38 1.98,
67.45 7.63, 93.5 8.56, and 98.21 7.52, respectively.
According to RT-PCR, we found that the expression of NF-
kBp65 was evidently reduced (Fig. 2) and indicated that
Ad-siRNA had silencing effect in chondrocytes.Fig. 3. Production of TNF-a in vivo following intra-articular injection of var
pression of TNF-a in synovial ﬂuid increased. And intra-articular injection
concentration of TNF-a in synovial ﬂuid aspirates, the lowest TNF-a co
synovial ﬂuid leukocytosis was noIN VIVO DOSE TITRATION STUDYAfter operation of knee, the expression of TNF-a in syno-
vial ﬂuid increased. And intra-articular injection of the Ad-
siRNANF-kBp65 leads to dose-depended decrease in the
concentration of TNF-a in synovial ﬂuid aspirates, the low-
est TNF-a concentration, which was the highest silencing
effect of Ad-siRNANF-kBp65, occurred with 1.6 108 pfu/ml
[Fig. 3(A)]. The marked, acute synovial ﬂuid leukocytosis
was not seen at any viral loads [Fig. 3(B)].b-GAL STAINING OF JOINTAfter injection of Ad-lacZ for 3 days, the joint was stained
with b-gal, cartilage and synovium of joint were stained
(Fig. 4). This indicated that adenovirus can infect into carti-
lage and synovium, and the gene of lacZ was expressed in
chondrocytes and synoviocytes.THE EFFECTS OF AD-siRNANF-kBp65 ON ACTIVATION OF
NF-kB IN CARTILAGEOn EMSA (Fig. 5), the protein of NF-kBp65 in cartilage of
OA had an obvious DNA binding (lane 4) in comparison with
the protein in normal cartilage (lane 2). However, transduc-
tion of Ad-siRNANF-kBp65 into cartilage showed a signiﬁcant
inhibition of NF-kB binding (lane 6), but Ad-siRNAscrambled
had no effect on NF-kB binding (lane 5). This binding reac-
tion was speciﬁc since unlabeled NF-kB probe prevented
the formation of the complexes with biotin-labeled NF-kB
probe (lane 3).ious amount of the Ad-siRNANF-kBp65: after induction of OA, the ex-
of the Ad-siRNANF-kBp65 leads to dose-depended decrease in the
ncentration occurred with 1.6 108 pfu/ml (A). The marked, acute
t seen at any viral loads (B).
Fig. 4. b-gal staining of joint: after injection of Ad-lacZ for 3 days,
the joint was stained with b-gal, cartilage and synovium of joint
were stained with blue.
Fig. 6. The effects of Ad-siRNA and aspirin on the expression of
IL-1b in the synovial ﬂuid of OA at 1 and 2 weeks after surgery.
#P< 0.01 vs OA without treatment, *P< 0.01 vs OA without treat-
ment, and þP< 0.01 vs treatment with aspirin.
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OF TNF-a AND IL-1b IN SYNOVIAL FLUID OF OATo examine the effects of Ad-siRNA on the expression of
TNF-a and IL-1b in synovial ﬂuid, the knees of OA were lav-
aged and analyzed with ELISA. At 1 week, the expression
of TNF-a and IL-1b in synovial ﬂuid in group 1 (OA without
treatment), group 2 (OA that injected with Ad-lacZ) and
group 3 (OA that injected with Ad-siRNAscrambled) was obvi-
ously increased compared with group 6 (normal), signiﬁ-
cantly decreased in group 4 (OA that treated with aspirin)
and group 5 (OA that treated with Ad-siRNANF-kBp65)
compared with group 3, and the expressions affected byFig. 5. The effect of Ad- siRNANF-kBp65 on NF-kB DNA binding in
cartilage: The protein of NF-kBp65 in cartilage of OA had an obvi-
ous DNA binding (lane 4) in comparison with the protein in normal
cartilage (lane 2). Ad-siRNANF-kBp65 could signiﬁcantly inhibit the
NF-kB binding (lane 6), but Ad-siRNAscrambled had no effect on
NF-kB binding (lane 5). This binding reaction was prevented with
a 200-fold excess unlabeled NF-kB probe (lane 3).Ad-siRNANF-kBp65 was decreased greater than those
affected by aspirin. At 2 weeks, the expression of TNF-
a and IL-1b was similar to those of 1 week. It should be
noted that the expression of TNF-a with Ad-siRNANF-kBp65
at 2 weeks was lower than the expression of group 6
(normal rats) (Figs. 6 and 7).THE EXPRESSION OF NF-kBp65 IN CARTILAGE
AND SYNOVIUMWestern blot revealed that the protein of NF-kBp65
in cartilage in group1 (OA without treatment), group 2
(OA that injected with Ad-lacZ) and group 3 (OA that
injected with Ad-siRNAscrambled) was signiﬁcantly increased
compared with group 6 (normal rats), and signiﬁ-
cantly decreased in group 5 (OA that treated with
Ad-siRNANF-kBp65) compared with group 3 (Fig. 8), the ex-
pression of NF-kBp65 in synovium was similar to that of car-
tilage (Fig. 9), except that effect of Ad-lacZ and Ad-siRNA
on synovial cells was greater than on chondrocytes. This in-
dicated that Ad-siRNA could transfect into chondrocytes
and synovial cells, and markedly inhibited the expression
of NF-kBp65. This also showed that the effect of Ad-siRNA
on synovial cells was more evident than on chondrocytes,Fig. 7. The effects of Ad-siRNA and aspirin on the expression of
TNF-a in the synovial ﬂuid of OA at 1 and 2 weeks after surgery.
#P< 0.01 vs OA without treatment, *P< 0.01 vs OA without treat-
ment, and þP< 0.01 vs treatment with aspirin.
Fig. 8. The effects of Ad-siRNA on the expression of NF-kBp65 in cartilage. The cartilage was collected at 2 weeks after surgery, the expres-
sion of NF-kBp65 was assessed at the level of protein by Western blot. The densitometric quantiﬁcation of NF-kBp65 was normalized to glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) and expressed as arbitrary units (AU). Representative Western blot analysis of NF-kBp65
and GAPDH is shown and graph shows the mean S.E.M. of the three independent experiments. *P< 0.01 vs control.
179Osteoarthritis and Cartilage Vol. 16, No. 2and synovium was more susceptible to adenovirus than
cartilage.HISTOLOGIC EVALUATION OF ARTICULAR CARTILAGESpecimens of group 1 at week 2 show a morphologic
change characteristic at early stage of OA. The total histo-
logic severity of lesions was similar in this group, transverse
clefts occurred and resulted in loss of articular cartilage
mass, ﬁbrosis occurred at the surface of cleft degenerative
cartilage, and several chondrocytes in one lacuna formed
a cluster in intermediate layers. Toluidine blue staining for
proteoglycan was distributed unevenly, the areas in the su-
perﬁcial and intermediate layers were mostly destained and
only the areas around cell clusters were still darkly stained
[Fig. 10(A) and (B)]. Group 2 and group 3 showed a similar
degree of morphologic change with group 1 at week 2
[Fig. 10(C) and (D), (E) and (F)].
In group 4, chondrocyte cloning decreased, cartilage de-
generation and proteoglycan loss and ﬁbrosis alleviated
compared with group 2 [Fig. 10(G) and (H)]. Group 5
showed a marked reduction in cartilage pathology, and de-
generation and ﬁbrosis of cartilage were slight. The loss of
proteoglycan in the cartilage was observed by decreased
staining with toluidine blue in the superﬁcial and intermedi-
ate layers, and cell clustered in the intermediate layers
[Fig. 10(I) and (J)]. As a control, normal cartilage sections
from group 6 are shown [Fig. 10(K) and (L)]. The grade of
severity of OA lesion in different groups was calculated,
and there were signiﬁcant difference between group 3,
group 4 and group 5 (Fig. 11).Fig. 9. The effects of Ad-siRNA on the expression of NF-kBp65 in syno
expression of NF-kBp65 was assessed at the level of protein by Western
toGAPDHandexpressed asAU.RepresentativeWestern blot analysis of N
the three independent experimeHISTOLOGY EVALUATION OF SYNOVIAL MEMBRANEWhen compared with synovium from group 6 [Fig. 12(A)],
sections from group 1, group 2 and group 3 showed a typical
synovitis of OA [Fig. 12(B), (C) and (D), respectively], the
synovium was dramatically thickened, highly ﬁbrous, and
hypercellular, with increased number of synoviocytes and
inﬁltrating mononuclear leukocytes. The rats treated with
aspirin had slightly smaller lesions on synovial sections
than the rats in group 1 [Fig. 12(E)]. Joints treated with
Ad-siRNANF-kBp65 showed a more slighter synovitis
[Fig. 12(F)], synovial sections from this group of rats were
more distinguishable from those from group 1 and group
3. The grade of severity of OA lesion in different groups
was calculated, there were signiﬁcant difference between
group 3, group 4 and group 5 (Fig. 13).Discussion
Although the etiology of OA is poorly understood, numer-
ous animal models that mimic aspects of the disease have
been developed to study the pathophysiology of the dis-
ease and to evaluate potential therapeutics. Besides
a model of monosodium iodoacetate-induced OA30, a vari-
ety of surgical models of OA in animals have been devised
to accelerate the degenerative changes that occur over long
periods of time in spontaneous OA. Some of the most com-
monly used models in larger animals are the Pondnuki
model (anterior cruciate ligament (ACL) transection) in
dog31, lateral meniscectomy in sheep32 and partial menis-
cectomy in rabbit33. Small animal models of surgical OAvium. The synovium was collected at 2 weeks after surgery, the
blot. The densitometric quantiﬁcation of NF-kBp65 was normalized
F-kBp65andGAPDH is shownandgraph shows themean S.E.M. of
nts. *P< 0.01 vs control.
Fig. 10. Representative sections of articular cartilage from the medial femoral condyle of OA at 2 weeks after surgery were stained with H
and E (left pane) and toluidine blue staining (right pane) of [(A) and (B)] OA without treatment, [(C) and (D)] OA that injected with Ad-lacZ,
[(E) and (F)] OA that injected with Ad-siRNAscrambled, [(G) and (H)] OA that treated with aspirin, [(I) and (J)] OA that received injection of
Ad-siRNANF-kBp65, and [(K) and (L)] rats that neither induced with arthritis nor treatment (100).
Fig. 11. Histologic grading of cartilage from femoral condyles of OA
joints of rats at 2 weeks after surgery. Values are the mean S.E.M.
total score (0e6 scale) of lesions from OA rats without treatment;
OA rats with intra-articular injection of Ad-lacZ; OA rats with intra-
articular injection of Ad-siRNAscrambled; OA rats treated with aspirin;
OA rats treated with intra-articular injection of Ad-siRNANF-kBp65
and rats that neither induced with arthritis nor treatment. Asterisks
(*) denote values which differ at P< 0.01.
181Osteoarthritis and Cartilage Vol. 16, No. 2have also been described including partial meniscectomy in
guinea-pig34, meniscus tear in the guinea-pig35 and ACL
transection in rat36. Janusz37 induced OA in rats by surgical
tear of the meniscus and found that moderate cartilage
degeneration of the tibial plateau was observed at week 1
after operation with focal loss of chondrocytes and
proteoglycan. The cartilage lesions increased slightly in
depth at week 2 with some areas of focally severe cartilageFig. 12. The representative sections of synovium from normal (A), OA (B
(D), OA treated with aspirin (E) and OA treated with Ad-siRNANF-kBdegeneration. In our study, at week 2 after operation, se-
vere cartilage degeneration with loss of chondrocytes and
proteoglycan was seen in femoral medial condyle; synovial
inﬂammation with severe degree of inﬂammatory reaction
which was characterized by synovial hyperplasia, ﬁbrosis
and inﬁltration with a mixed mononuclear cell was seen in
all synovium. These pathological changes resembled the
characteristics of OA.
In recent years, much interest has centered on the role of
cytokines in the pathogenesis in OA. IL-1b and TNF-a are
considered to be the principal inﬂammatory cytokines. San-
dra38 studied in induced murine streptococcal cell wall
arthritis and found that the involvement of TNF-a in this
model was limited to joint swelling, whereas IL-1b played
a dominant role in cartilage destruction and inﬂammatory
cell inﬂux. Clinical trials also revealed that the level of
TNF-a and IL-1b in joint ﬂuid of an ACL injured knee was
high39. TNF-a neutralization substantially relieved arthritis
symptoms, such as pain and number of swollen joints40,41,
and the trial with IL-1Ra suggested that IL-1 blocking results
in amelioration of joint erosion42,43. Therefore, some re-
searches for therapy of OA were focused on IL-1b and
TNF-a. Julio44 transferred IL-1Ra gene in vivo to treat rabbit
knee joint OA, and Frisbie14 delivered IL-1Ra gene in vivo
to treat experiment equine OA. They all indicated that
IL-1Ra could signiﬁcantly reduce the progression of exper-
imental OA. Seon45 delivered IL-1Ra and soluble TNF
receptor (sTNFR) into antigen-induced arthritis that antago-
nized the effects of IL-1b and TNF-a, and found that the
co-delivery of both IL-1Ra and sTNFR resulted in a syner-
gistic effects in disease amelioration.
NF-kB induces rapid expression of multiple genes in-
volved in immune and inﬂammatory responses. It regulates), OA injected with Ad-lacZ (C), OA injected with Ad-siRNAscrambled
p65 (F) at 2 weeks after surgery with H and E staining (200).
Fig. 13. Histologic grading of synovial membrane from OA joints of
rats at 2 weeks after surgery. The samples were quantitatively clas-
siﬁed according to synovium hypercellularity and the extent of sy-
novitis. Values are the mean S.E.M. total score (0e3 scale) of
lesions from OA rats without treatment; OA rats with intra-articular
injection of Ad-lacZ; OA rats with intra-articular injection of Ad-siR-
NAscrambled; OA rats treated with aspirin; OA rats treated with intra-
articular injection of Ad-siRNANF-kBp65 and rats that neither induced
with arthritis nor treatment. Asterisks (*) denote values which differ
at P< 0.01.
182 L. X. Chen et al.: siRNA suppress the progression of experimental OAthe expression of IL-1b and TNF-a and is also activated by
these two genes, which may lead to a feed-forward ampliﬁ-
cation, with chronic activation of NF-kB in certain cells46. So
we attempted to interrupt the signal pathway of NF-kB, cut
into this feed-forward ampliﬁcation and explore an approach
to treat OA. Tetsuya47 found that intra-articular transfection
of NF-kB decoy oligodeoxynucleotides in arthritic joints of
rats with collagen-induced arthritis using the hemagglutinat-
ing virus of Japan-liposome method led to an amelioration
of arthritis. In this study, we used adenoviral vector to trans-
fer NF-kBp65-speciﬁc siRNA into the knee joints of rat OA
model and observed that Ad-siRNA could inhibit the expres-
sion of NF-kBp65 in cartilage and synovium, NF-kBp65-
speciﬁc siRNA could inhibit the activation of NF-kB in
cartilage, the expression of IL-1b and TNF-a in synovial
ﬂuid and suppress the progression of OA with reduction of
cartilage degeneration and alleviation of synovitis. This indi-
cated that adenoviral vector could effectively transfer siRNA
into chondrocytes and synoviocytes and lead the siRNA to
exert silencing effect, and NF-kBp65 played a key role in
mediation of TNF-a and IL-1b.
siRNAs are short, double-stranded RNA molecules that
can target mRNAs with complementary sequence for deg-
radation via a cellular process termed RNA interference
(RNAi)48. Researchers in many disciplines employ RNAi
to analyze gene function in mammalian cells. The siRNAs
used in early studies were typically prepared in vitro or by
chemical synthesis and transfected into cells. Some labora-
tories directly used siRNA in vivo in studies49e51, and they
reported the use of a rapid injection method to deliver a large
volume of physiological solution containing siRNAs into the
tail vein of mice, and demonstrated the effectiveness of this
method in reducing target gene expression in cells through-
out the body. In another study, injection of liposomes con-
taining siRNAs directed against the mRNA-encoding
agouti-related peptide resulted in an increase in metabolic
rate and reduced body weight without a change in food
intake52. More recent publications feature plasmids, and
expression cassettes made by PCR that include RNApolymerase promoters upstream of a hairpin siRNA tem-
plate. This strategy of introducing an siRNA template into
cells, and taking advantage of endogenous RNA polymer-
ases to transcribe double-stranded RNA (dsRNA) can
also be used with adenoviral vectors25. Upon introduction
into mammalian cells, the siRNA template is transcribed,
producing a 19-mer hairpin siRNA. The hairpin siRNA is
recognized by Dicer, the nuclease responsible for activating
dsRNAs for the RNAi pathway, and is cleaved to form func-
tional siRNA. Adenoviral vectors are episomal, thus, siR-
NAs are expressed transiently, and have been extensively
used to express genes in postmitotic neurons and tumor
in vivo53e55. There are several reasons why viral vectors
are used in basic and applied RNAi research. One major
reason is that expression vectors allow continuous produc-
tion of siRNAs in cells and, therefore, sustained depletion of
the protein encoded by the targeted mRNA. A second rea-
son is that the transfection efﬁciency of certain types of
cells, particularly postmitotic cells can be greatly increased.
A third advantage of viral vectors is that they are typically
more effective in obtaining sustained expression and gene
silencing in vivo56. Our study indicates that adenoviral vec-
tor can deliver siRNA into cells of cartilage and synovium.
Gelse57 injected Ad-lacZ (1 109 pfu) into mouse knee
joint and found that Ad-lacZ infected the entire joint space
and positively stained cells were still found 2 weeks after
the injection. Kuboki58 injected the adenovirus suspension
into the joints of guinea-pigs and did not ﬁnd any hypertro-
phy in the superﬁcial cells of the synovium, or marked inﬁl-
tration of inﬂammatory cells, and no distant expression of
the delivered genes observed. So we injected Ad-siRNA
into rat knee joints with 1.6 108 pfu, and observed the
changes of cytokines in synovial ﬂuid, cartilage and syno-
vium at 2 weeks after surgery. Although the expression of
IL-1b and TNF-a and the scores of synovium and cartilage
in Ad-lacZ groups were more obvious compared with OA
groups, there were no signiﬁcant differences between two
groups. And the marked, acute synovial ﬂuid leukocytosis
was not seen at any joints.
Acetylsalicylic acid (aspirin) is a non-steroidal anti-
inﬂammatory drug (NSAID) widely used for its anti-inﬂam-
matory, antipyretic and anti-rheumatic properties59,60, and
can prevent TNF-a- and IL-1-induced NF-kB activation in
a dose-dependent manner through inhibition of phosphor-
ylation and degradation of IkBa and IkBb61. Therefore we
used aspirin to treat control rats in our study, and found
that aspirin could lessen the expression of TNF-a and
IL-1b, and slightly alleviate synovitis and degradation of
cartilage.
Since NF-kB is a known cell survival signal for most cells,
we realize that chronic and long-term reduction of basal NF-
kB could lead to cell death or apoptosis. However, we
believe that this could still be an effective anti-inﬂammatory
intervention under disease and stimulated conditions. Im-
portantly, the technology of siRNA which is a gene knock-
down, not a gene knockout, can only decrease the
increased levels of expression of catabolic genes in the
early phase of OA, but cannot completely block conduction
of the signal of NF-kB. So we conclude that although the
precise mechanism of siRNA remains uncertain, it is likely
that adenovirus mediated NF-kBp65-speciﬁc siRNA could
be developed as a powerful approach to restrain the induc-
tion of IL-1b and TNF-a, alleviate the inﬂammation of syno-
vium and reduce the degradation of cartilage in early phase
of OA model. Further observations on optimization of infec-
tive condition, long-term effect of Ad-siRNANF-kBp65 and
effects on other organize are needed.
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